Looking for leads, investment insights, or competitive intelligence?
News about Bristol-Myers Squibb
Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.
Chinese drug regulators gave the nod to Bristol-Myers Squibb’s immune therapy star Opdivo. Dozens of companies are hoping they’re next.
A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half.
Merck gained more than $5.7 billion in market value Monday.
Drug giants Merck and Bristol-Myers Squibb felt the pain, too.